Lupus erythematosus - Lupus Érythematosus
☆ Dina hasil Stiftung Warentest 2022 ti Jerman, kapuasan konsumen sareng ModelDerm ngan ukur langkung handap tibatan konsultasi telemedicine anu mayar.
Nembongan salaku erythema rada purplish.
Ruam kukupu nu ilaharna muncul dina beungeut.
References
Ngidentipikasi sareng ngagolongkeun cutaneous lupus erythematosus (CLE) nyababkeun tangtangan diagnostik, ngabédakeunana tina systemic lupus erythematosus kalayan keterlibatan kulit. Panaliti panganyarna ngajelaskeun faktor genetik, lingkungan, sareng imunologis anu aya dina CLE. Induksi narkoba sacara khusus muncul salaku salah sahiji pemicu anu paling penting pikeun CLE. Pangobatan ngalibatkeun terapi topikal sareng sistemik, kalebet biologis anu ngajangjikeun (belimumab, rituximab, ustekinumab, anifrolumab, BIIB059) , kalayan efektivitas nunjukkeun dina uji klinis.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Cutaneous lupus erythematosus (CLE) nyertakeun rupa-rupa masalah kulit, sababaraha diantarana tiasa nyambung ka masalah kaséhatan anu langkung lega. Éta dikategorikeun kana sababaraha jinis, sapertos acute CLE (ACLE) , sub-acute CLE (SCLE) , and chronic CLE (CCLE) . CCLE ngawengku discoid lupus erythematosus (DLE) , LE profundus (LEP) , chilblain cutaneous lupus, and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Lupus erythematosus mangrupikeun sakelompok panyakit otoimun anu tiasa mangaruhan sababaraha bagian awak. Sababaraha jinis, sapertos systemic lupus erythematosus (SLE) , mangaruhan sababaraha organ, sedengkeun anu sanésna, sapertos cutaneous lupus erythematosus (CLE) , utamina mangaruhan kulit. Kami ngagolongkeun sababaraha jinis CLE dumasar kana campuran tanda klinis, pamariksaan jaringan, sareng tes getih, tapi aya seueur variasi antara individu. Masalah kulit sering berkembang kusabab faktor sapertos paparan sinar panonpoé, ngaroko, atanapi pangobatan anu tangtu.
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Anu ngabalukarkeun lupus érythematosus (lupus erythematosus) teu jelas. Di antara kembar idéntik, lamun salah sahiji kapangaruhan aya 24% kasempetan nu sejen bakal ogé. Hormon séks awéwé, sinar panonpoé, ngaroko, kakurangan vitamin D, sareng sababaraha inféksi ogé dipercaya ningkatkeun résiko.
Pangobatan tiasa kalebet NSAID, kortikosteroid, immunosuppressants, hydroxychloroquine, sareng methotrexate. Sanajan corticosteroids éféktif, pamakéan jangka panjang ngakibatkeun efek samping.